# ISP 2014

# Program at a Glance

	September 19, Friday		
	Plenary Room	Posters	Conference Room 6
8:00 -	8:00-9:25 Session 7 Tumor Biology and Experimental Model (II) Chairpersons : Anne-Paule Gimenez-Roqueplo (France) Isamu Miyamori (Japan)		
9:00 -			
10:00 -	9:25-9:35 Coffee break 9:35-11:30 Session 8 Recent Advances in the Treatment of Malignant Pheochromocytoma (Co-sponsored by Progenics Pharmaceuticals, Inc.) Chairpersons : Henri Timmers (The Netherlands) Mitsuhide Naruse (Japan)	9:00-16:15 Poster Display	
11:00 -		i oster Display	
12:00 -	11:30-12:15 Session 9 Free Oral Communication Chairpersons : Katsutoshi Takahashi (Japan) / Takamasa Ichijo (Japan)		
13:00 -	12:20-13:20 Luncheon Seminar 2 (Co-sponsored by DAIICHI SANKYO Company, Ltd.) Chairperson : Mitsuhide Naruse (Japan)		12:20-13:20 Working Group(II)
14:00 -		13:30-14:50 Poster Session (II)	
15:00 -	14:50-15:30 Session 10 Surgical Approach Chairpersons : Osamu Ogawa (Japan) / Shinichi Suzuki (Japan)		
16:00 -	15:30-16:10 Session 11 Histopathology Chairpersons : Takanobu Yoshimoto (Japan) / Noriko Kimura (Japan)		
17:00 -			
18:00 -	18:00-21:00		
19:00 -	Temple Tour and Gala Reception (Buffet Style) @Kodai-ji Temple and THE SODOH HIGASHIYAMA ※Shuttle buses will be operated.		
20:00 -			

### 8:00~9:25 Session 7 Tumor Biology and Experimental Model (II)

Chairpersons: Anne-Paule Gimenez-Roqueplo

Service de Génétique, HEGP & INSERM UMR970, Team 13, PARCC@HEGP, Assistance Hôpitaux de Paris & INSERM, France Isamu Miyamori

Internal Medicine, Uchinada Onsen Hospital, Japan

- 7-1 Thirty-five years of pheochromocytoma models- where do we stand today? Arthur S. Tischler Pathology and Laboratory Medicine, Tufts Medical Center and Tufts University School of Medicine, Boston, MA, United States of America
- 7-2 Development of new experimental models for Pheochromocytoma by using patient-derived iPS cells Eijiro Nakamura

Graduate School of Medicine, Kyoto University, Kyoto, Japan

7-3 Pseudohypoxic metabolic transformation in SDH-deficient cells Daniel A Tennant School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom

# 7-4 A hypoxia-MYC/MAX pathway explains the heterogeneous phenotypic features of chromaffin cell tumors

Nan Qin

Universitty Hospital Dresden, Technische Universitt Dresden, Dresden, Germany

## 9:35~11:30

## Session 8 Recent Advances in the Treatment of Malignant Pheochromocytoma Co-Sponsored by Progenics Pharmaceuticals, Inc

### **Chairpersons: Henri Timmers**

Internal Medicine / Endocrinology, Radboud University Medical Center, The Netherlands Mitsuhide Naruse

Division of Endocrinology, Metabolism, and Hypertension, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan

# 8-1 New Horizons in Targeted Therapy for Malignant Phaeochromocytomas and Paragangliomas

### Ashley B. Grossman

Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, United Kingdom

# 8-2 Treatment Options for Patients with Metastatic Pheochromocytomas and Paragangliomas, Where do we stand?

### Eric Baudin

Département de Médecine Nucléaire et de Cancérologie Endocrinienne, Institut Gustave Roussy, Université Paris Sud, Paris, France

8-3 Development of Clinical Trials in the Times of Personalized Cancer Medicine Camilo Jimenez Vasquez

Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America

### Plenary Room (Conference Room C)

### 8-4 Impact of CVD therapy on the prognosis in patients with malignant pheochromocytoma/paraganglioma Takuyuki Katabami Division of Metabolism and Endocrinology, Department of Internal Medicine, St Marianna University

Division of Metabolism and Endocrinology, Department of Internal Medicine, St Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Kanagawa, Japan

# 8-5 Targeted radionuclide therapy for malignant neuroendocrine tumors: Current status and future perspective in Japan

#### Seigo Kinuya

Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan

### 11:30~12:15

### Session 9 Free Oral Communication

### Chairpersons: Katsutoshi Takahashi

Nephrology and Endocrinology, University of Tokyo Hospital, Japan

### Takamasa Ichijo

The Department of Diabetes and Endocrine, Saiseikai Yokohamashi Tobu Hospital, Japan

9-1 Analysis of Glucose Intolerance in Pheochromocytoma/Paraganglioma Patients Naoko Hashimoto

Graduate School of Medicine, Chiba University, Chiba, Japan

# 9-2 Preoperative metyrosine improves cardiovascular outcomes for pheochromocytoma and paraganglioma resection

### Heather Wachtel

- Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, United States of America

- Department of Surgery, University of Pennsylvania, United States of America

# 9-3 Astatine-211-meta-astatobenzylguanidine (<sup>211</sup>At-MABG) in targeted-alpha-therapy for pheochromocytoma

### Daniel A Pryma

Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, PA, United States of America

## 12:20~13:20 Luncheon Seminar 2 : Co-Sponsored by DAIICHI SANKYO Company, Ltd.

### Chairperson: Mitsuhide Naruse

Division of Endocrinology, Metabolism, and Hypertension, Clinical Research Institute, Kyoto Medical Center, National Hospital Organization, Kyoto, Japan

LS-2 Visceral fat obesity and aldosterone over-secretion: existence of aldosteronestimulating factor in sera of idiopathic hyperaldosteronism (IHA) patients Hiroshi Itoh

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

### 14:50~15:30 Session 10 Surgical Approach

### Chairpersons: Osamu Ogawa

Department of Urology, Kyoto University Graduate School of Medicine, Japan Shinichi Suzuki Department of Thyroid and Endocrinology, Fukushima Medical University School of Medicine, Japan

### 10-1 Surgical Approaches for Treating Pheochromocytoma Tadashi Matsuda Department of Urology and Andrology, Kansai Medical University, Hirakata, Japan

### 10-2 Management of adrenal tumors with possible invasion to adjacent organs Toyone Kikumori

Department of Breast and Endocrine Surgery, Nagoya University Hospital, Nagoya, Aichi, Japan

## 15:30~16:10

### Session 11 Histopathology

### Chairpersons: Takanobu Yoshimoto

Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Japan

### Noriko Kimura

Department of Clinical Research, Pathology Division, National Hospital Organization Hakodate Hospital, Japan

# 11-1 New developments in the pathology of pheochromocytomas, paragangliomas and related secondary tumours

### Ronald R. de Krijger

Dept. of Pathology, Erasmus MC, Rotterdam, The Netherlands, and Reinier de Graaf Hospital, Delft, Rotterdam, The Netherlands

11-2 Pathological diagnosis related to molecular and transcription profiles on phaeochromocytoma and paraganglioma

### Noriko Kimura

Pathology, National Hospital Organization Hakodate Hospital, Hakodate, Hokkaido, Japan